Myung In Pharmaceutical (A317450) Stock Overview

A pharmaceutical company, manufactures ETC and OTC drugs. More details

A317450 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 55.3% below our estimate of its fair value

Earnings grew by 8.8% over the past year

Risk Analysis

Shares are highly illiquid

A317450 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Myung In Pharmaceutical LTD. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Myung In Pharmaceutical
Historical stock prices
Current Share Price	₩82,200.00
52 Week High	₩134,500.00
52 Week Low	₩80,800.00
Beta	0
1 Month Change	-29.02%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-32.57%

Recent updates

Shareholder Returns

	A317450	KR Pharmaceuticals	KR Market
7D	-9.6%	7.1%	4.0%
1Y	n/a	9.7%	56.8%

Return vs Industry: Insufficient data to determine how A317450 performed against the KR Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how A317450 performed against the KR Market.

Price Volatility

Is A317450's price volatile compared to industry and market?
A317450 volatility
A317450 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	3.8%
Market Average Movement	4.8%
10% most volatile stocks in KR Market	10.4%
10% least volatile stocks in KR Market	2.3%

Stable Share Price: A317450's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: Insufficient data to determine A317450's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1985	n/a	Hang-Myung Lee	myunginph.co.kr

Myung In Pharmaceutical LTD., a pharmaceutical company, manufactures ETC and OTC drugs. It offers products in the areas of thrombosis and anti-platelet, anti-hypertensive, anti-angina, anti-parkinson, anti-dementia, anti-epileptics, anti-schizophrenia, anti-depressants, adhd, anti-insomnia, gum disease treatment, gastrointestinal, cold-cough medicine, anti-fever, anti-pain, anti-inflammation agent, nutrition supplements and other pharmaceuticals. The company also provides APIs, such as benztropine mesylate, benidipine hcl, clopidogrel bisulfate, haloperidol, paroxetine hcl, pimozide, quetiapine fumarate, rasagiline mesylate, risperidone, sumatriptan succinate, trazodone hci, triazolam, levetiracetam, carbamazepine, benserazide hydrochloride, escitalopram oxalate, vortioxetine hbr, brivaracetam, edoxban tosylate, opicapone, brexpiprazole, guanfacine hydrochloride, lacosamide, lurasidone hydrochloride.

Myung In Pharmaceutical LTD. Fundamentals Summary

How do Myung In Pharmaceutical's earnings and revenue compare to its market cap?
A317450 fundamental statistics
Market cap	₩1.20t
Earnings (TTM)	₩77.92b
Revenue (TTM)	₩280.62b

15.4x

P/E Ratio

4.3x

P/S Ratio

Is A317450 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A317450 income statement (TTM)
Revenue	₩280.62b
Cost of Revenue	₩110.30b
Gross Profit	₩170.32b
Other Expenses	₩92.40b
Earnings	₩77.92b

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	5.34k
Gross Margin	60.69%
Net Profit Margin	27.77%
Debt/Equity Ratio	0%

How did A317450 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/02 05:35
End of Day Share Price	2025/10/31 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Myung In Pharmaceutical LTD. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Myung In Pharmaceutical LTD.KOSE:A317450 Stock Report